

# Christopher J Earley

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9348818/christopher-j-earley-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119  
papers

9,095  
citations

53  
h-index

95  
g-index

126  
ext. papers

10,456  
ext. citations

4.3  
avg, IF

6.07  
L-index

#	Paper	IF	Citations
119	Toward a better definition of the restless legs syndrome. The International Restless Legs Syndrome Study Group. <i>Movement Disorders</i> , <b>1995</b> , 10, 634-42	7	745
118	Restless legs syndrome: a review of clinical and pathophysiologic features. <i>Journal of Clinical Neurophysiology</i> , <b>2001</b> , 18, 128-47	2.2	407
117	Augmentation of the restless legs syndrome with carbidopa/levodopa. <i>Sleep</i> , <b>1996</b> , 19, 205-13	1.1	369
116	An algorithm for the management of restless legs syndrome. <i>Mayo Clinic Proceedings</i> , <b>2004</b> , 79, 916-22	6.4	240
115	Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. <i>Brain</i> , <b>2009</b> , 132, 2403-12	11.2	236
114	Clinical practice. Restless legs syndrome. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 2103-9	59.2	236
113	An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. <i>Sleep</i> , <b>2004</b> , 27, 560-83	1.1	233
112	Evaluating the quality of life of patients with restless legs syndrome. <i>Clinical Therapeutics</i> , <b>2004</b> , 26, 925-35	3.5	227
111	Iron and The Restless Legs Syndrome. <i>Sleep</i> , <b>1998</b> , 21, 381-387	1.1	221
110	Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. <i>Sleep Medicine</i> , <b>2007</b> , 8, 520-30	4.6	212
109	The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. <i>Sleep Medicine</i> , <b>2013</b> , 14, 675-84	4.6	210
108	The four diagnostic criteria for Restless Legs Syndrome are unable to exclude confounding conditions ("mimics"). <i>Sleep Medicine</i> , <b>2009</b> , 10, 976-81	4.6	208
107	Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease). <i>Sleep Medicine</i> , <b>2014</b> , 15, 1288-301	4.6	200
106	The role of iron in restless legs syndrome. <i>Movement Disorders</i> , <b>2007</b> , 22 Suppl 18, S440-8	7	197
105	MRI-determined regional brain iron concentrations in early- and late-onset restless legs syndrome. <i>Sleep Medicine</i> , <b>2006</b> , 7, 458-61	4.6	185
104	Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. <i>Sleep Medicine</i> , <b>2000</b> , 1, 11-19	4.6	184
103	Insight into the pathophysiology of restless legs syndrome. <i>Journal of Neuroscience Research</i> , <b>2000</b> , 62, 623-8	4.4	174

102	Profile of altered brain iron acquisition in restless legs syndrome. <i>Brain</i> , <b>2011</b> , 134, 959-68	11.2	173
101	Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. <i>Sleep</i> , <b>1996</b> , 19, 801-10	1.1	167
100	The treatment of restless legs syndrome with intravenous iron dextran. <i>Sleep Medicine</i> , <b>2004</b> , 5, 231-5	4.6	163
99	Cognitive deficits associated with restless legs syndrome (RLS). <i>Sleep Medicine</i> , <b>2006</b> , 7, 25-30	4.6	157
98	The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 261-4	7.1	142
97	Restless legs syndrome: understanding its consequences and the need for better treatment. <i>Sleep Medicine</i> , <b>2010</b> , 11, 807-15	4.6	138
96	Validation of the Johns Hopkins restless legs severity scale. <i>Sleep Medicine</i> , <b>2001</b> , 2, 239-242	4.6	137
95	Evidence-based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. <i>Sleep Medicine</i> , <b>2018</b> , 41, 27-44	4.6	131
94	A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. <i>Sleep Medicine</i> , <b>2011</b> , 12, 440-4	4.6	129
93	Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. <i>Lancet Neurology</i> , <b>2017</b> , 16, 898-907	24.1	121
92	Thalamic glutamate/glutamine in restless legs syndrome: increased and related to disturbed sleep. <i>Neurology</i> , <b>2013</b> , 80, 2028-34	6.5	117
91	Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. <i>Sleep Medicine</i> , <b>2011</b> , 12, 906-13	4.6	109
90	The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome. <i>Sleep</i> , <b>2011</b> , 34, 341-7	1.1	109
89	Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. <i>Mayo Clinic Proceedings</i> , <b>2013</b> , 88, 977-86	6.4	107
88	A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. <i>Sleep Medicine</i> , <b>2009</b> , 10, 206-11	4.6	101
87	Epidemiology of restless legs syndrome in Korean adults. <i>Sleep</i> , <b>2008</b> , 31, 219-23	1.1	101
86	Repeated IV doses of iron provides effective supplemental treatment of restless legs syndrome. <i>Sleep Medicine</i> , <b>2005</b> , 6, 301-5	4.6	92
85	Ferritin levels in the cerebrospinal fluid and restless legs syndrome: effects of different clinical phenotypes. <i>Sleep</i> , <b>2005</b> , 28, 1069-75	1.1	90

84	Validation of the Restless Legs Syndrome Quality of Life questionnaire. <i>Value in Health</i> , <b>2005</b> , 8, 157-67	3.3	89
83	Validation of the Hopkins telephone diagnostic interview for restless legs syndrome. <i>Sleep Medicine</i> , <b>2008</b> , 9, 283-9	4.6	86
82	Restless legs syndrome augmentation associated with tramadol. <i>Sleep Medicine</i> , <b>2006</b> , 7, 592-3	4.6	80
81	Pregnancy accounts for most of the gender difference in prevalence of familial RLS. <i>Sleep Medicine</i> , <b>2010</b> , 11, 310-3	4.6	76
80	Increased synaptic dopamine in the putamen in restless legs syndrome. <i>Sleep</i> , <b>2013</b> , 36, 51-7	1.1	75
79	The Johns Hopkins telephone diagnostic interview for the restless legs syndrome: preliminary investigation for validation in a multi-center patient and control population. <i>Sleep Medicine</i> , <b>2003</b> , 4, 137-41	4.6	71
78	Iron deficiency alters dopamine uptake and response to L-DOPA injection in Sprague-Dawley rats. <i>Journal of Neurochemistry</i> , <b>2008</b> , 106, 205-15	6	69
77	Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. <i>Sleep Medicine</i> , <b>2009</b> , 10, 123-8	4.6	68
76	Augmentation as a treatment complication of restless legs syndrome: concept and management. <i>Movement Disorders</i> , <b>2007</b> , 22 Suppl 18, S476-84	7	67
75	Ferritin subunits in CSF are decreased in restless legs syndrome. <i>Translational Research</i> , <b>2006</b> , 147, 67-73		64
74	The dopaminergic neurons of the A11 system in RLS autopsy brains appear normal. <i>Sleep Medicine</i> , <b>2009</b> , 10, 1155-7	4.6	63
73	Is ferroportin-hepcidin signaling altered in restless legs syndrome?. <i>Journal of the Neurological Sciences</i> , <b>2006</b> , 247, 173-9	3.2	62
72	Postmortem and imaging based analyses reveal CNS decreased myelination in restless legs syndrome. <i>Sleep Medicine</i> , <b>2011</b> , 12, 614-9	4.6	60
71	Circadian changes in CSF dopaminergic measures in restless legs syndrome. <i>Sleep Medicine</i> , <b>2006</b> , 7, 263-8	4.6	58
70	Thy1 expression in the brain is affected by iron and is decreased in Restless Legs Syndrome. <i>Journal of the Neurological Sciences</i> , <b>2004</b> , 220, 59-66	3.2	57
69	CSF dopamine, serotonin, and biopterin metabolites in patients with restless legs syndrome. <i>Movement Disorders</i> , <b>2001</b> , 16, 144-9	7	57
68	Mitochondrial ferritin in the substantia nigra in restless legs syndrome. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2009</b> , 68, 1193-9	3.1	55
67	Brain iron deficiency in idiopathic restless legs syndrome measured by quantitative magnetic susceptibility at 7 tesla. <i>Sleep Medicine</i> , <b>2016</b> , 22, 75-82	4.6	54

66	New Insights into the Neurobiology of Restless Legs Syndrome. <i>Neuroscientist</i> , <b>2019</b> , 25, 113-125	7.6	52
65	Functional connectivity alternation of the thalamus in restless legs syndrome patients during the asymptomatic period: a resting-state connectivity study using functional magnetic resonance imaging. <i>Sleep Medicine</i> , <b>2014</b> , 15, 289-94	4.6	52
64	Lower molecular weight intravenous iron dextran for restless legs syndrome. <i>Sleep Medicine</i> , <b>2013</b> , 14, 274-7	4.6	45
63	Response to intravenous iron in patients with iron deficiency anemia (IDA) and restless leg syndrome (Willis-Ekbom disease). <i>Sleep Medicine</i> , <b>2014</b> , 15, 1473-6	4.6	42
62	The effects of dietary iron deprivation on murine circadian sleep architecture. <i>Sleep Medicine</i> , <b>2006</b> , 7, 634-40	4.6	42
61	Pivotal Role of Adenosine Neurotransmission in Restless Legs Syndrome. <i>Frontiers in Neuroscience</i> , <b>2017</b> , 11, 722	5.1	39
60	Low brain iron effects and reversibility on striatal dopamine dynamics. <i>Experimental Neurology</i> , <b>2014</b> , 261, 462-8	5.7	38
59	Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. <i>Sleep Medicine</i> , <b>2016</b> , 25, 16-23	4.6	38
58	The Appropriate Use of Opioids in the Treatment of Refractory Restless Legs Syndrome. <i>Mayo Clinic Proceedings</i> , <b>2018</b> , 93, 59-67	6.4	37
57	Targeting hypersensitive corticostriatal terminals in restless legs syndrome. <i>Annals of Neurology</i> , <b>2017</b> , 82, 951-960	9.4	37
56	Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation. <i>Sleep Medicine</i> , <b>2017</b> , 31, 71-77	4.6	33
55	Diurnal cycle influences peripheral and brain iron levels in mice. <i>Journal of Applied Physiology</i> , <b>2009</b> , 106, 187-93	3.7	32
54	Altered iron metabolism in lymphocytes from subjects with restless legs syndrome. <i>Sleep</i> , <b>2008</b> , 31, 847-52		32
53	Adenosine receptors as markers of brain iron deficiency: Implications for Restless Legs Syndrome. <i>Neuropharmacology</i> , <b>2016</b> , 111, 160-168	5.5	31
52	Systems genetic analysis of the effects of iron deficiency in mouse brain. <i>Neurogenetics</i> , <b>2012</b> , 13, 147-53		30
51	Segregation analysis of restless legs syndrome: possible evidence for a major gene in a family study using blinded diagnoses. <i>Human Heredity</i> , <b>2006</b> , 62, 157-64	1.1	29
50	Gray matter alteration in patients with restless legs syndrome: a voxel-based morphometry study. <i>Clinical Imaging</i> , <b>2015</b> , 39, 20-5	2.7	28
49	Iron deficiency alters the day-night variation in monoamine levels in mice. <i>Chronobiology International</i> , <b>2009</b> , 26, 447-63	3.6	27

48	Proteomic analysis of the cerebrospinal fluid of patients with restless legs syndrome/Willis-Ekbom disease. <i>Fluids and Barriers of the CNS</i> , <b>2013</b> , 10, 20	7	26
47	Prevalence and clinical characteristics of patients with restless legs syndrome with painful symptoms. <i>Sleep Medicine</i> , <b>2015</b> , 16, 775-8	4.6	25
46	In search of alternatives to dopaminergic ligands for the treatment of restless legs syndrome: iron, glutamate, and adenosine. <i>Sleep Medicine</i> , <b>2017</b> , 31, 86-92	4.6	24
45	Systems genetic analysis of peripheral iron parameters in the mouse. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>2007</b> , 293, R116-24	3.2	23
44	Diurnal variation of default mode network in patients with restless legs syndrome. <i>Sleep Medicine</i> , <b>2018</b> , 41, 1-8	4.6	21
43	Altered white matter integrity in primary restless legs syndrome patients: diffusion tensor imaging study. <i>Neurological Research</i> , <b>2014</b> , 36, 769-74	2.7	21
42	RLS and blood donation. <i>Sleep Medicine</i> , <b>2009</b> , 10, 844-9	4.6	21
41	Default mode network disturbances in restless legs syndrome/Willis-Ekbom disease. <i>Sleep Medicine</i> , <b>2016</b> , 23, 6-11	4.6	20
40	Association of restless legs syndrome variants in Korean patients with restless legs syndrome. <i>Sleep</i> , <b>2013</b> , 36, 1787-91	1.1	20
39	Systems genetic analysis of multivariate response to iron deficiency in mice. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>2012</b> , 302, R1282-96	3.2	20
38	Up-regulation of striatal adenosine A(2A) receptors with iron deficiency in rats: effects on locomotion and cortico-striatal neurotransmission. <i>Experimental Neurology</i> , <b>2010</b> , 224, 292-8	5.7	19
37	Restless legs syndrome and periodic leg movements in sleep. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2011</b> , 99, 913-48	3	18
36	A direct interaction between two Restless Legs Syndrome predisposing genes: MEIS1 and SKOR1. <i>Scientific Reports</i> , <b>2018</b> , 8, 12173	4.9	16
35	MATPLM1, A MATLAB script for scoring of periodic limb movements: preliminary validation with visual scoring. <i>Sleep Medicine</i> , <b>2015</b> , 16, 1541-9	4.6	16
34	Diminished iron concentrations increase adenosine A(2A) receptor levels in mouse striatum and cultured human neuroblastoma cells. <i>Experimental Neurology</i> , <b>2009</b> , 215, 236-42	5.7	15
33	Investigation into the correlation between sensation and leg movement in restless legs syndrome. <i>Movement Disorders</i> , <b>2005</b> , 20, 1097-103	7	13
32	Efficacy of ferric carboxymaltose (FCM) 500mg dose for the treatment of Restless Legs Syndrome. <i>Sleep Medicine</i> , <b>2018</b> , 42, 7-12	4.6	12
31	Dissociative changes in the Bmax and KD of dopamine D2/D3 receptors with aging observed in functional subdivisions of the striatum: a revisit with an improved data analysis method. <i>Journal of Nuclear Medicine</i> , <b>2012</b> , 53, 805-12	8.9	10

30	The Management of Restless Legs Syndrome: An Updated Algorithm. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 1921-1937	6.4	10
29	Co-registration of magnetic resonance spectroscopy and transcranial magnetic stimulation. <i>Journal of Neuroscience Methods</i> , <b>2015</b> , 242, 52-7	3	8
28	A comparison of MRI tissue relaxometry and ROI methods used to determine regional brain iron concentrations in restless legs syndrome. <i>Medical Devices: Evidence and Research</i> , <b>2015</b> , 8, 341-50	1.5	8
27	Moderate to severe but not mild RLS is associated with greater sleep-related sympathetic autonomic activation than healthy adults without RLS. <i>Sleep Medicine</i> , <b>2020</b> , 68, 89-95	4.6	8
26	Inter-movement interval as a primary stable measure of periodic limb movements of sleep. <i>Sleep Medicine</i> , <b>2016</b> , 17, 138-43	4.6	8
25	Iron-deficiency and dopaminergic treatment effects on RLS-Like behaviors of an animal model with the brain iron deficiency pattern of the restless legs syndrome. <i>Sleep Medicine</i> , <b>2020</b> , 71, 141-148	4.6	7
24	Latest guidelines and advances for treatment of restless legs syndrome. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75, e08	4.6	6
23	Extracellular vesicles reveal abnormalities in neuronal iron metabolism in restless legs syndrome. <i>Sleep</i> , <b>2019</b> , 42,	1.1	5
22	Allocating provider resources to diagnose and treat restless legs syndrome: a cost-utility analysis. <i>Sleep Medicine</i> , <b>2017</b> , 38, 44-49	4.6	4
21	Resting-state connectivity and the effects of treatment in restless legs syndrome. <i>Sleep Medicine</i> , <b>2020</b> , 67, 33-38	4.6	4
20	Defining morphology of periodic leg movements in sleep: an evidence-based definition of a minimum window of sustained activity. <i>Sleep and Breathing</i> , <b>2016</b> , 20, 1293-1299	3.1	4
19	We need to do better: A systematic review and meta-analysis of diagnostic test accuracy of restless legs syndrome screening instruments. <i>Sleep Medicine Reviews</i> , <b>2021</b> , 58, 101461	10.2	4
18	Intervening Leg Movements Disrupt PLMS Sequences. <i>Sleep</i> , <b>2017</b> , 40,	1.1	3
17	Neuroimaging in Restless Legs Syndrome <b>2009</b> , 78-82		3
16	Akathisia and Restless Legs Syndrome: Solving the Dopaminergic Paradox. <i>Sleep Medicine Clinics</i> , <b>2021</b> , 16, 249-267	3.6	3
15	Evidence for communication of peripheral iron status to cerebrospinal fluid: clinical implications for therapeutic strategy. <i>Fluids and Barriers of the CNS</i> , <b>2020</b> , 17, 28	7	3
14	Assessment of change in restless legs syndrome symptoms during the acute drug-withdrawal period. <i>Sleep Medicine</i> , <b>2018</b> , 52, 80-87	4.6	2
13	Response to Clinical Corners case (Sleep Medicine 6/2: 83-4): Pregnancy associated with daytime sleepiness and nighttime restlessness. <i>Sleep Medicine</i> , <b>2005</b> , 6, 475	4.6	2

12	Developing a behavioral model of Restless Legs Syndrome utilizing mice with natural variances in ventral midbrain iron. <i>Sleep Medicine</i> , <b>2020</b> , 71, 135-140	4.6	1
11	Another dopamine agonist for treatment of restless legs syndrome. <i>Lancet Neurology, The</i> , <b>2011</b> , 10, 675-7	24.1	1
10	Iron Dysregulation in Restless Legs Syndrome <b>2009</b> , 61-68		1
9	Pilot study: can machine learning analyses of movement discriminate between leg movements in sleep (LMS) with vs. without cortical arousals?. <i>Sleep and Breathing</i> , <b>2021</b> , 25, 373-379	3.1	1
8	Developing a biomarker for restless leg syndrome using genome wide DNA methylation data. <i>Sleep Medicine</i> , <b>2021</b> , 78, 120-127	4.6	1
7	Randomized, placebo-controlled trial of ferric carboxymaltose in restless legs syndrome patients with iron deficiency anemia. <i>Sleep Medicine</i> , <b>2021</b> , 84, 179-186	4.6	1
6	Insight into the pathophysiology of restless legs syndrome <b>2000</b> , 62, 623		1
5	Response to the letter "Characterization of the painful restless legs syndrome". <i>Sleep Medicine</i> , <b>2015</b> , 16, 1448	4.6	0
4	The Safety and Efficacy of Pregabalin Add-on Therapy in Restless Legs Syndrome Patients.. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 786408	4.1	0
3	Response to "Characterization of the painful restless legs syndrome". <i>Sleep Medicine</i> , <b>2015</b> , 16, 898	4.6	
2	Altered expression of iron-management proteins in the brain microvasculature of Restless Legs Syndrome. <i>FASEB Journal</i> , <b>2008</b> , 22, 1191.5	0.9	
1	Role of Striatal A2A Receptor Subpopulations in Neurological Disorders <b>2013</b> , 179-197		